Immuneering Overview

  • Founded
  • 2008

Founded
  • Status
  • Public

  • Employees
  • 74

Employees
  • Stock Symbol
  • IMRX

Stock Symbol
  • Share Price
  • $6.37

  • (As of Tuesday Closing)

Immuneering General Information

Description

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Stock Exchange
NAS
Primary Office
  • 245 Main Street
  • 2nd Floor
  • Cambridge, MA 02142
  • United States
+1 (617) 000-0000

Immuneering Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immuneering Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.37 $6.63 $3.74 - $24.75 $175M 26.4M 55.8K

Immuneering Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 254,767 276,684
Revenue 506 2,080 2,312 1,920
EBITDA (48,341) (33,854) (17,003) (7,398)
Net Income (48,052) (33,536) (17,040) (7,709)
Total Assets 133,692 166,705 38,423 14,099
Total Debt 4,851 5,365 621 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Immuneering Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Immuneering‘s full profile, request access.

Request a free trial

Immuneering Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Immuneering‘s full profile, request access.

Request a free trial

Immuneering Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debili
Drug Discovery
Cambridge, MA
74 As of 2022
00000
0000 0000-00-00
00000000 00000

000000

sectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim
0000 000000000
Brisbane, CA
00 As of 0000
000.00
00000000000 000.00

000000

ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolor
0000000000000
Berkeley, CA
000 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Immuneering Competitors (15)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Second Genome Venture Capital-Backed Brisbane, CA 00 000.00 00000000000 000.00
0000000 0000000000 Formerly VC-backed Berkeley, CA 000 00000 00000000 00000
00000000 000000 00 Formerly VC-backed Baltimore, MD 000 00000 000000&0 00000
00000000 Venture Capital-Backed Houston, TX 00 00.000 000000000 00.000
0000000000 Formerly VC-backed Menlo Park, CA 000 00000 00000000 00000
You’re viewing 5 of 15 competitors. Get the full list »

Immuneering Patents

Immuneering Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3166636-A1 Mek inhibitors and therapeutic uses thereof Pending 10-Jan-2020 0000000000
EP-4087840-A1 Mek inhibitors and therapeutic uses thereof Pending 10-Jan-2020 0000000000
AU-2021206684-A1 Mek inhibitors and therapeutic uses thereof Pending 10-Jan-2020 0000000000
US-11043305-B1 Systems and methods for rapid gene set enrichment analysis Active 02-Feb-2018 000000000 00
EP-3019865-A4 Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition Inactive 12-Jul-2013 G16B20/00 0
To view Immuneering’s complete patent history, request access »

Immuneering Executive Team (9)

Name Title Board Seat Contact Info
Benjamin Zeskind Ph.D Chief Executive Officer & Founder
Mallory Morales Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Leah Neufeld Chief People Officer
Brett Hall Chief Scientific Officer
Bob Carpenter Co-Founder & Chairman
You’re viewing 5 of 9 executive team members. Get the full list »

Immuneering Board Members (7)

Name Representing Role Since
Ann Berman Immuneering Board Member, Member of the Nominating and Corporate Governance Committee & Chair of the Audit Committee 000 0000
Bob Carpenter Immuneering Co-Founder & Chairman 000 0000
Diana Hausman MD Immuneering Board Member 000 0000
Joseph Kekst Self Board Member 000 0000
Laurie Keating JD Immuneering Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Immuneering Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immuneering Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Immuneering‘s full profile, request access.

Request a free trial